News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diosynth Biotechnology (Research Triangle Park) Announces Extension Of Commercial Supply Agreement With PDL BioPharma, Inc. (PDLI) For The Manufacture Of Retavase(R)


2/7/2007 12:27:48 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma, Inc. for the commercial manufacture of Retavase® (reteplase), a fibrinolytic agent that has been marketed in North America since October 1996. Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES